Last reviewed · How we verify
Beclometasone
At a glance
| Generic name | Beclometasone |
|---|---|
| Also known as | Clenil, Clenil 200 |
| Sponsor | Imperial College London |
| Target | Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Allergic rhinitis
- Asthma
- Asthma management
- Nasal polyp
- Rhinitis
- Vasomotor rhinitis
Common side effects
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclometasone CI brief — competitive landscape report
- Beclometasone updates RSS · CI watch RSS
- Imperial College London portfolio CI